Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Fineline Cube Jan 10, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Fineline Cube Jan 11, 2026
Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Fineline Cube Jan 10, 2026
Company Drug

Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors

Fineline Cube Apr 28, 2025

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...

Company Deals

Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility

Fineline Cube Apr 28, 2025

Shanghai-listed biopharmaceutical company Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) has announced plans to invest...

Company Drug

Biokin’s BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers

Fineline Cube Apr 28, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company

Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply

Fineline Cube Apr 28, 2025

German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China)...

Company Drug

CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors

Fineline Cube Apr 28, 2025

Zhejiang-based Zhejiang Shimai Pharmaceutical Co.,Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...

Company Drug

Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy

Fineline Cube Apr 28, 2025

US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...

Company Drug

Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors

Fineline Cube Apr 28, 2025

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...

Company Medical Device

Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China

Fineline Cube Apr 28, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC,...

Company Medical Device

Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Apr 28, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has secured marketing approval...

Others

Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics

Fineline Cube Apr 28, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported Q1 2025 financials with global group...

Company

BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline

Fineline Cube Apr 28, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...

Company

Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China

Fineline Cube Apr 27, 2025

Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors

Fineline Cube Apr 27, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received regulatory clearance...

Company Drug

InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for First-line CLL/SLL Treatment

Fineline Cube Apr 27, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has obtained regulatory approval from...

Company Deals

Chipscreen Biosciences Cuts Private Placement Proceeds to RMB 950 Million

Fineline Cube Apr 27, 2025

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has revised its private placement proceeds to RMB...

Company Drug

Shanghai Junshi Biosciences’ Loqtorzi Receives NMPA Approval for Melanoma Treatment

Fineline Cube Apr 27, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received another...

Company Drug

Innovent Biologics’ Aoyixin Wins NMPA Approval for First-line NSCLC Treatment

Fineline Cube Apr 27, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another indication approval from...

Company Drug

CSPC Pharmaceutical Group Gains NMPA Approval for SYH2068 siRNA Clinical Trials

Fineline Cube Apr 27, 2025

China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has obtained approval from China’s National Medical Products...

Company Deals

Grand Pharma Group and Sirtex Medical US Launch Commercial Partnership in Medical Innovation

Fineline Cube Apr 27, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its subsidiary Chengdu Shetai Medical...

Company Deals Drug

Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)

Fineline Cube Apr 27, 2025

China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South...

Posts pagination

1 … 110 111 112 … 606

Recent updates

  • Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal
  • Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC
  • Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D
  • Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
  • InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.